Newbridge Financial Services Group’s DiaMedica Therapeutics DMAC Stock Holding History

Newbridge Financial Services Group’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,269	Closed	-$3K	–	1402
2022 Q2	$3K	Hold	1,269	–	–	﹤0.01%	1100
2022 Q1	$3K	Sell	1,269 -241	-16%	-$684	﹤0.01%	1191
2021 Q4	$6K	Hold	1,510	–	–	﹤0.01%	1027
2021 Q3	$6K	Buy	1,510 +997	+194%	+$3.82K	﹤0.01%	972
2021 Q2	$2K	Hold	513	–	–	﹤0.01%	1266
2021 Q1	$5K	Buy	513 +86	+20%	+$803	﹤0.01%	1019
2020 Q4	$4K	Hold	427	–	–	﹤0.01%	880
2020 Q3	$2K	Buy	+427	New	+$2.26K	﹤0.01%	911

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Newbridge Financial Services Group's DMAC Position: Q3 2022 in Review

Newbridge Financial Services Group sold out of DiaMedica Therapeutics (DMAC) in Q3 2022, closing a stake of 1,269 shares — an estimated $3K sold.

Newbridge Financial Services Group first reported a position in DMAC in Q3 2020 and held it in 8 quarters. The position peaked at $6K in Q4 2021. 26 funds tracked by Wall St. Rank hold DMAC as of Q3 2022.

Newbridge Financial Services Group reported no remaining DiaMedica Therapeutics position as of Q3 2022 after selling out during the quarter.
Newbridge Financial Services Group sold 1,269 DiaMedica Therapeutics shares in Q3 2022, an estimated $3K.
Newbridge Financial Services Group first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 8 quarters.
Newbridge Financial Services Group's DiaMedica Therapeutics position peaked at $6K in Q4 2021.
26 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2022.

Based on Newbridge Financial Services Group's 13F filing for Q3 2022, filed 13 Oct 2022.